Minerva Neurosciences Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
at Jefferies, and thank you for joining me today. It is my pleasure to have Remy Luthringer, CEO of Minerva, joining me. Welcome, Remy. Thank you so much for having me.
Yes. Of course. Always a great pleasure to be here.
Great. Remy, for those in the audience less familiar with the Minerva story, can you please give us an overview of what you're working on and what you're trying to achieve milestones over the next 12 months?
Yeah. We are working on probably one of the highest unmet medical needs in the space of psychiatry, which are negative symptoms in patients diagnosed with schizophrenia. As you know, schizophrenia is mostly three types of symptoms. The positive symptoms, hallucination, agitation, and this is what is currently treated with existing treatments, with the antipsychotics. You have some cognitive impairment, and you have negative symptoms, and it's very clear that the negative symptoms are the symptoms which are impairing the functioning of these patients. A lot of people have tried. I think we have been very successful with one study. The second study showed that the highest dose we are testing now in a confirmatory study was also successful. We are trying really to address one of the highest unmet medical needs in the space of psychiatry.
Mm-hmm. You're running a confirmatory study right now. What's the timeline for that?
This study will be in two parts. Part A, which is a 12-week study, treatment versus placebo. This will read out during the second half of next year. Obviously, more we are advancing in terms of recruitment, more closer or more precise can we be. But for the moment, we are really focusing on second half of next year. This will be followed by a second part of the study, which is called phase B, and this is focusing on safety, mostly looking to relapses, because obviously what we are proposing is a paradigm shift. A paradigm shift being that you don't continuously treat patients with antipsychotics, because there is a population out there, which is probably 60% of the patients with a diagnostic of schizophrenia, who can benefit from our drug in monotherapy.
This is part B, is looking to a direct comparison in terms of relapses of positive symptoms between antipsychotics and our drug.
Mm-hmm. To be clear, do any of these antipsychotics out there help with negative symptoms? Or is it Yeah. I think the short answer is no, they don't help.
They even have a tendency to worsen negative symptoms, because when we speak about negative symptoms, we can speak about primary or disease-related negative symptoms, and we have what we call secondary negative symptoms, which can be induced, for example, by antipsychotics. They don't help, yeah. I think is a fair answer.
Okay. Then remind us how big the population is in the U.S.
In the U.S., people who have the, how to say, the disease is around 3.2 million people. It is a very, very large population. It is more than 1% of the population. When you think about patients who are treated or seen by the medical system, it is about 2.2 million people. When you are going according to our criteria, having negative symptoms or impairing negative symptoms and having some stability in their symptoms, it is around 900,000 patients. Our target, once the drug will get approved, I mean, it is about 900,000 patients.
I see. Quite large population.
Right. And so, you kind of hinted at it earlier is, should you be approved as a monotherapy, how do you use this exactly in relation to the antipsychotics?
I think what will happen here is that people will remember why antipsychotics have been developed. Antipsychotics have been developed as major tranquilizers, so to take care about an acute episode of psychosis. Why, I mean, you are prescribing antipsychotics, and I am coming from the clinical side, yes, I mean, I have prescribed antipsychotics as well, is because, I mean, it is reducing somehow the level of relapses, the number of relapses, and the hospitalization. But it is not treating negative symptoms, it is worsening negative symptoms. So, what will happen is that our target population, where we have shown over one year stability of the positive symptoms, an extremely low relapse rate, and I mean, if people are interested, I can show even the slide, is to treat the patients, monotherapy with our drug.
If there is a relapse, you can use the antipsychotic to treat the acute episode of relapse. So, we are going back to the basics of the disease and of how an antipsychotic is working, or where it is the most useful, let me put it like this.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
